Type 2 & other diabetes

Efficacy and Hypoglycaemia Outcomes With Once‐Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1–3 Trials

Diabetes Obes MetabPublished Post hoc analysis of the COMBINE 1–3 randomised trials

Authors' conclusion

Efficacy and hypoglycaemia outcomes with IcoSema versus comparators were generally consistent among adults with T2D with mild to moderate kidney impairment or impaired liver function.

Study context

Population
Adults with T2D, by kidney (eGFR ≥90; 60–<90; 30–<60; <30 mL/min/1.73 m²) and liver (total bilirubin ≤21 μmol/L or AST ≤31/≤37 [female/male] U/L vs higher) function subgroupsCOMBINE 1–3
Comparison
Once-weekly IcoSema vs comparators
Methodological detailssubgroup analysis by kidney and liver function
  • Subgroup analysis by kidney and liver function

Primary result

As reported in the abstract

Treatment by kidney/liver function subgroup interactions: change in HbA1c, change in body weight, rates of clinically significant or severe hypoglycaemia · baseline to week 52
No statistically significant treatment by subgroup interactions for change in HbA1c, body weight or combined clinically significant or severe hypoglycaemia rates (hypoglycaemia not assessed by kidney function for COMBINE 2)
all p > 0.05

Further findings

HbA1c <7.0% without weight gain and without clinically significant or severe hypoglycaemia

Significant treatment by kidney function subgroup interaction in COMBINE 3, not COMBINE 1 or 2
P < 0.05
Significant treatment by liver function subgroup interaction in COMBINE 1, not COMBINE 2 or 3
P < 0.05

Mean weekly total insulin dose

COMBINE 1 and 3: significant treatment by kidney function subgroup interactions; no significant treatment by liver function subgroup interactions

Original publication

Efficacy and Hypoglycaemia Outcomes With Once‐Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1–3 Trials. Diabetes Obes Metab. Published 5 August 2026. doi:10.1111/dom.70895

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.